MedTrace Logo

Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

NCT06895941 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-04-08

No results posted yet for this study

Summary

The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.

Conditions

  • Lung Cancer (NSCLC)
  • Neoadjuvant Immunotherapy

Interventions

DIAGNOSTIC_TEST

PET

Exploring the predictive value of PET/CT metabolic parameters for the efficacy of neoadjuvant immunotherapy in non-small cell lung cancer.

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2027-04-01
Completion
2027-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06895941 on ClinicalTrials.gov